In the third quarter, Hims & Hers Health reported revenue of $599 million, representing a 49% year-over-year increase and surpassing consensus estimates by 5%. The company added 95,000 net new subscribers during the period, bringing total subscribers to 1.35 million. Average revenue per subscriber rose by 12% compared to the prior year, driven by higher uptake of specialty telehealth services and diagnostic offerings. Gross margin expanded by 200 basis points to 68%, reflecting operational leverage in its direct-to-consumer model and higher margins on new prescription treatments.

Hims & Hers has rolled out enhanced AI-enabled care modules across its platform, including personalized treatment matching algorithms that integrate patient-reported outcomes and real-time biomarker tracking. The company has onboarded over 50,000 users onto its new at-home lab testing kits, generating longitudinal data that feeds into machine learning models. These investments are expected to support a 15% reduction in treatment churn and improve cross-sell conversion rates by up to 20%, as care pathways become more tailored to individual health profiles.

Management highlighted ongoing discussions to renew and expand its partnership on a next-generation GLP-1 therapy, with a potential co-development agreement that could add $300 million in annualized revenue by 2028. The recently announced $200 million share repurchase authorization underscores confidence in the company’s valuation. International markets remain a key focus, with entry into three European countries slated for mid-2026, representing a $1 billion revenue opportunity over the next three years. Analysts maintain a buy rating, citing sticky, high-margin customer cohorts and robust free cash flow generation expected to exceed $150 million next fiscal year.